Allergy Therapeuti (AGYTF) Upgraded to “Hold” at Zacks Investment Research
Zacks Investment Research upgraded shares of Allergy Therapeuti (NASDAQ:AGYTF) from a sell rating to a hold rating in a report released on Wednesday morning.
According to Zacks, “Allergy Therapeutics Plc is a specialty pharmaceutical company focused on allergy vaccination. The company’s product pipeline consists of PollinexTrees(R), Pollinex Grasses + Rye(R), Skin Prick Testing, Diagnostic Products and Service. Allergy Therapeutics Plc is based in Worthing, the United Kingdom. “
Shares of Allergy Therapeuti (NASDAQ:AGYTF) opened at 0.39 on Wednesday. Allergy Therapeuti has a 12 month low of $0.33 and a 12 month high of $0.39. The firm’s 50-day moving average price is $0.39 and its 200-day moving average price is $0.39. The firm’s market capitalization is $231.44 million.
Receive News & Stock Ratings for Allergy Therapeuti Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeuti and related stocks with our FREE daily email newsletter.